Amoxicillin/clavulanate therapy of respiratory tract infections: a microbiologic perspective.
The development of beta-lactamase-producing strains of the common respiratory tract pathogens Hemophilus influenzae and Moraxella catarrhalis has caused increasing resistance to a number of antimicrobial agents, including ampicillin and amoxicillin, that are traditionally used to treat respiratory tract infections. Because antimicrobial therapy for upper and lower respiratory tract infections is usually empiric, an understanding of beta-lactamase-mediated resistance and its implications for antibiotic therapy is critical for the successful treatment of these infections.
Cunha
B A
BA
Infectious Disease Division, Winthrop-University Hospital, Mineola, New York.
D000658:Amoxicillin / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002969:Clavulanic Acids / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006193:Haemophilus influenzae / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000201:enzymology; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D001618:beta-Lactamases